Why Shares of Affimed Fell Thursday
Shares of German immuno-oncology company Affimed Therapeutics (NASDAQ: AFMD) were down a little more than 15% on Thursday afternoon. There was no big news from the biotech company, but clinical-stage biotechs are considered riskier stocks than most, and with the markets dropping in general on Thursday, Affimed's shares took a hit. Investors are waiting to hear next month how two clinical trials are faring for one of the company's lead therapies in AFM13.